Shop Now Contact

Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar)

Cat # Size Price Quantity
5010011 mg$250
5010025 mg$750
50100320 mg$2000

  Bulk/Custom

Product Details

CloneBriakinumab
ApplicationNeutralization, Intracellular Flow cytometry, animal model study
Host SpeciesMammalian cells
ReactivityHuman
FormatLiquid
Product DescriptionAnti-Human IL-12 / IL-23 (Briakinumab Biosimilar)
IsotypeHuman IgG1
Regulatory StatusRUO
ClonalityRecombinant
ImmunogenHuman IL-12 / IL-23
Species specificityHuman
Purity>95% by reducing SDS-PAGE
GradeIn vivo
Min Sample Size1 mg
Storage Conditions4ºC
Maximal Shelf Life12 months
Synonymsp40
Target NameIL-12/IL-23
Research AreasCytokines, Inflammation
See All FormatsClone Briakinumab

Background Information

Briakinumab is a recombinant, fully human monoclonal antibody that belongs to the immunoglobulin G1 (IgG1) subclass. It is designed to specifically bind to the shared p40 subunit of the cytokines interleukin-12 (IL-12) and interleukin-23 (IL-23), thereby interfering with their interaction with the interleukin-12 receptor β1 (IL-12Rβ1) on the surface of immune cells. Structurally, Briakinumab is a typical IgG1 molecule composed of two identical heavy chains and two identical light chains connected by disulfide bonds, forming a Y-shaped configuration. It has an approximate molecular weight of 148 kilodaltons (kDa) and is produced using mammalian expression systems, such as Chinese Hamster Ovary (CHO) cells, to ensure proper glycosylation and protein folding consistent with human antibodies.

The variable regions of the heavy and light chains in Briakinumab contain complementarity-determining regions (CDRs), which define its antigen-binding specificity. These regions form a paratope that engages with the p40 subunit of IL-12 and IL-23 through non-covalent interactions, including hydrogen bonding and van der Waals forces. By binding to the p40 subunit, Briakinumab prevents IL-12 and IL-23 from interacting with their receptor complexes on T cells and natural killer (NK) cells. This inhibition disrupts downstream signaling through the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway, limiting the production of proinflammatory cytokines such as interferon-gamma (IFN-γ) and interleukin-17 (IL-17) in experimental systems.

The Fc region of Briakinumab provides structural stability, prolongs its serum half-life by interacting with neonatal Fc receptors (FcRn), and maintains effector functions characteristic of IgG1 antibodies. It is glycosylated at the asparagine 297 residue within the CH2 domain, contributing to molecular solubility and conformation.

Data Sheets

Anti-Human IL-12 / IL-23 (Briakinumab Biosimilar) TDS

Related Products

Anti-Human IL-12 / IL-23 (Ustekinumab Biosimilar), Clone Ustekinumab

Frequently Asked Questions

What are InnoCyto Biosimilar products?
InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.
How similar are these biosimilars to the original therapeutic antibody?
Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.
Are these antibodies suitable for in vivo studies?
Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.
What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?
A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.
What quality and purity standards do biosimilar antibodies meet?
All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.
Which therapeutic targets and mechanisms are covered in the Biosimilar line?
The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.